DTR’s news round-up 2019: the stories that defined the year
Drug Target Review lists its 10 most popular news stories from 2019, summarising the drug targets that you wanted to read about.
List view / Grid view
Drug Target Review lists its 10 most popular news stories from 2019, summarising the drug targets that you wanted to read about.
A mechanism has been revealed that could be used to deny RAS mutant tumour cells (which is known to encourage the growth seen in pancreatic cancer patients) of a key survival mechanism.
This article highlights some of the most recent drug target discoveries that could be used to develop and design a treatment for pancreatic cancer.
A study conducted on human pancreatic tumours transplanted in mice reveals promise for an effective therapy in the future, say researchers.
A study has demonstrated that a novel vaccine design for pancreatic cancer has been successful in mice, doubling survival time.
Peptide-based nanoparticles have been designed which can suppress pancreatic cancer growth without the toxic side effects.
Cells containing Meflin play a role in restraining the progression of pancreatic cancer and could lead to new therapies against the disease.
Researchers have shown that blocking a particular enzyme causes chemotherapy to become more effective against pancreatic cancers in pre-clinical studies.
Researchers have developed a new cocktail of drugs that shrink pancreatic tumours in mice by blocking pathways that cancer cells use.
New findings show that the environment for pancreatic cancers plays a role in its metastasis, revealing a new potential drug target.
Using a compound called PTC596 in combination with other drugs, researchers effectively treated pancreatic cancer in mice.
Scientists have found a way to target and knock out a protein which is widely involved in pancreatic cancer cell growth, survival and invasion.
An antibody has been developed to block a protein secreted by the cells surrounding ovarian and pancreatic cancer tumours.
A study has discovered that a biomarker associated with pancreatitis is involved in its development to pancreatic cancer.
In a recent study in mice, researchers have found a way to deliver specific drugs to parts of the body that are exceptionally difficult to access.